Nuvectis Pharma reported net income of -$30.07M for the quarter ended Sep 2026. This income statement covers 23 quarters of results from Mar 2021 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating items | |||||||||||||||||||||||
| Research & DevelopmentR&D | 1.14M | 1.81M | 2.51M | 4.52M | 4.40M | 2.37M | 4.26M | 4.49M | 4.27M | 2.66M | 2.94M | 2.82M | 4.50M | 3.68M | 3.61M | 5.77M | 5.09M | 4.11M | 4.68M | 27.37M | |||
| Selling, General & AdministrativeSG&A | 1.12M | 1.14M | 1.07M | 1.42M | 2.38M | 1.73M | 1.51M | 1.67M | 2.60M | 1.74M | 1.70M | 1.54M | 1.95M | 1.89M | 2.98M | 2.02M | 2.53M | 2.15M | 2.51M | 3.68M | |||
| Operating ExpensesOpex | 2.27M | 2.95M | 3.57M | 5.94M | 6.78M | 4.10M | 5.77M | 6.16M | 6.87M | 4.40M | 4.64M | 4.36M | 6.45M | 5.57M | 6.60M | 7.79M | 7.62M | 6.26M | 7.20M | 31.05M | |||
| Operating IncomeOp. Inc | -2.27M | -2.95M | -3.57M | -5.94M | -6.78M | -4.10M | -5.77M | -6.16M | -6.87M | -4.40M | -4.64M | -4.36M | -6.45M | -5.57M | -6.60M | -7.79M | -7.62M | -6.26M | -7.20M | -31.05M | |||
| Non-operating items | |||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.00M | 0.00M | 0.06M | 0.08M | 0.05M | 0.06M | 0.28M | 0.24M | 0.23M | 0.22M | 0.21M | 0.20M | 0.24M | 0.26M | 0.33M | 0.30M | 0.21M | 0.18M | 0.98M | ||||
| Net income details | |||||||||||||||||||||||
| EBIT | -2.27M | -2.95M | -3.57M | -5.94M | -6.78M | -4.10M | -5.77M | -6.16M | -6.87M | -4.40M | -4.64M | -4.36M | -6.45M | -5.57M | -6.60M | -7.79M | -7.62M | -6.26M | -7.20M | -31.05M | |||
| EBT | -2.27M | -2.94M | -3.57M | -5.88M | -6.70M | -4.05M | -5.71M | -5.88M | -6.62M | -4.17M | -4.43M | -4.15M | -6.25M | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M | -7.02M | -30.07M | |||
| Income After Tax | -2.27M | -2.94M | -3.57M | -5.88M | -6.70M | -4.05M | -5.71M | -5.88M | -6.62M | -4.17M | -4.43M | -4.15M | -6.25M | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M | -7.02M | -30.07M | |||
| Income from Continuing OperationsIncome (Continuing) | -2.27M | -2.94M | -3.57M | -5.88M | -6.70M | -4.05M | -5.71M | -5.88M | -6.62M | -4.17M | -4.43M | -4.15M | -6.25M | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M | -7.02M | -30.07M | |||
| Consolidated Net IncomeConsol Net Inc. | -2.27M | -2.94M | -3.57M | -5.88M | -6.70M | -4.05M | -5.71M | -5.88M | -6.62M | -4.17M | -4.43M | -4.15M | -6.25M | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M | -7.02M | -30.07M | |||
| Income towards Parent CompanyParent Net Inc | -2.26M | -2.94M | -3.57M | -5.88M | -6.70M | -4.05M | -5.71M | -5.88M | -6.62M | -4.17M | -4.43M | -4.15M | -6.25M | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M | -7.02M | -30.07M | |||
| Net Income towards Common StockholdersNet Income | -2.26M | -2.94M | -3.57M | -5.88M | -6.70M | -4.05M | -5.71M | -5.88M | -6.62M | -4.17M | -4.43M | -4.15M | -6.25M | -5.33M | -6.33M | -9.89M | -7.31M | -6.05M | -7.02M | -30.07M | |||
| Additional items | |||||||||||||||||||||||
| EPS (Basic) | -0.53 | -0.32 | -0.28 | -0.42 | -0.53 | -0.27 | -0.38 | -0.37 | -0.43 | -0.25 | -0.26 | -0.24 | -0.37 | -0.27 | -0.30 | -0.44 | -0.34 | -0.26 | -0.30 | -1.02 | |||
| EPS (Diluted) | -0.53 | -0.32 | -0.28 | -0.42 | -0.53 | -0.27 | -0.38 | -0.37 | -0.43 | -0.25 | -0.26 | -0.24 | -0.37 | -0.27 | -0.30 | -0.44 | -0.34 | -0.26 | -0.30 | -1.02 | |||
| Shares Outstanding | 4.27M | 9.16M | 12.72M | 14.05M | 12.66M | 14.72M | 15.18M | 16.10M | 15.56M | 16.56M | 16.90M | 17.23M | 17.11M | 19.94M | 21.37M | 22.72M | 21.81M | 23.41M | 23.48M | 29.47M | |||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 4.27M | 9.16M | 12.72M | 14.05M | 12.66M | 14.72M | 15.18M | 16.10M | 15.56M | 16.56M | 16.90M | 17.23M | 17.11M | 19.94M | 21.37M | 22.72M | 21.81M | 23.41M | 23.48M | 29.47M | |||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 4.51M | 9.16M | 12.72M | 14.64M | 12.66M | 16.01M | 17.22M | 17.31M | 17.42M | 18.36M | 18.75M | 18.99M | 19.50M | 23.63M | 23.88M | 25.64M | 25.68M | 26.53M | 26.69M | 34.39M |
Pull Nuvectis Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=NVCT&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "NVCT", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=NVCT&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();